48 results
6-K
EX-99.1
SPRC
SciSparc Ltd
9 Feb 21
SciSparc Initiates Commercial Production of its CannAmide™ Pills
8:36am
Exhibit 99.1
SciSparc Initiates Commercial Production of its CannAmide™ Pills
The Anti-Inflammatory, Chronic Pain Treatment Is Expected … relieve chronic pain, the tablets will be marketed to pharmacies and other retail outlets across Canada following our entering into a distribution
6-K
EX-99.1
SPRC
SciSparc Ltd
31 Jul 19
Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement
4:03pm
) for the recommended use as an anti-inflammatory and to help relieve chronic pain.
This license is issued by Health Canada under the authority of the Natural … times daily. CannAmide was approved for the use as an anti-inflammatory to help relieve chronic pain.
Chronic pain is estimated to affect 38% of people
6-K
SPRC
SciSparc Ltd
26 Mar 19
Report of Foreign Private Issuer
4:08pm
treatment clinics to treat an assortment of different pains, including, acute pain, spine pain, chronic headaches, cancer pain, oral/maxillofacial pain … -110 in the treatment of chronic low back pain (the “Program”). As of the date hereof, enrollment for this iIND has not been initiated
6-K
EX-99.1
SPRC
SciSparc Ltd
31 Oct 23
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
8:15am
to 2030. The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected … market growth in chronic pain treatment, and that the Company is able to offer effective and safe treatments. Historical results of scientific research
6-K
EX-99.1
SPRC
SciSparc Ltd
5 Jan 21
Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada
9:12am
Health Products Directorate (NNHPD) for the recommended use as an anti-inflammatory and to help relieve chronic pain.
Chronic pain is estimated
6-K
EX-99.2
pfzd p982mqb
9 Oct 20
Interim Consolidated Financial Statements
12:00am
6-K
EX-99.1
5mkyjasnm83p4hwe
6 Jun 18
Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
4:55pm
6-K
EX-99.1
61k6zxtiz38et2
12 Jun 23
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
7:02am
6-K
EX-99.1
f48wlux89jlzc3b61
4 Aug 21
SciSparc Announces Completion of Corporate Rebranding and Launch of New Website
4:44pm
6-K
EX-99.1
t5c0su ynew
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
6-K
EX-99.1
8uo1k
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-99.1
k1ol9bn4opeex 10a
28 Jul 21
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome
4:00pm
6-K
EX-99.1
2k8 rlzbl77ym5dh
11 Feb 21
SciSparc Announces Rebranding and Business Updates
10:01am
6-K
EX-99.1
t8tl98hj4f0gcb
29 Jun 22
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
8:36am
6-K
EX-99.1
6k39zj
26 May 22
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
8:33am
6-K
EX-99.1
0d6jrphz
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm
6-K
EX-99.1
fnq9z zqz9a2q
10 Feb 21
SciSparc Engages Procaps for Development and Production of CannAmide™ and its SCI-110 Product Candidate
8:33am
6-K
EX-99.1
9z7wg31 r60ykym4bk
24 Feb 21
SciSparc Corporate Presentation February 2021
9:27am
6-K
EX-99.1
k9kv87n367skuohgx
2 Aug 22
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
4:00pm
6-K
EX-99.2
uc55t7 4raux
22 Apr 20
Therapix Biosciences Announces Appointment of New CEO
5:30pm